Clinical Trial

The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk

Study acronym: ALL-VASCOR
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Numerous studies, but not all, have suggested a positive effect of allopurinol on the cardiovascular system. The ALL-VASCOR study aims to evaluate the efficacy of allopurinol therapy for improving cardiovascular outcomes in patients at high and very high cardiovascular risk, excluding ischemic heart disease. This is particularly important due to the high cost of cardiovascular disease treatment and its status as one of the leading causes of death.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-07-05; most recent amendment 2025-01-03.
Status change: Not Yet Recruiting → Recruiting 2023-10-11
Trial Details
NCT Number NCT05943821
Lead Sponsor Poznan University of Medical Sciences
Conditions Cardiovascular Diseases, Uric Acid
Enrollment 1,116 participants
Start Date 2023-09-01
Primary Completion 2028-07-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-06